XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
  CTVS
  Transplantation
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Surgery Channel
subscribe to Surgery newsletter

Latest Research : Surgery

   DISCUSS   |   EMAIL   |   PRINT
CoreTherm® Treats Enlarged Prostates Faster and Effectively
May 24, 2005, 10:34, Reviewed by: Dr.

"CoreTherm is the most advanced, effective treatment for BPH available today. It provides patients with maximum positive results with minimal risk or discomfort. Physicians like CoreTherm because it allows them treat a greater number of patients in a shorter amount of time, thus making the biggest improvement to their patient's conditions and quality of life."

 
AUA Annual Convention 2005, Hall D, Booth 1768 -- Prostalund®, Inc., a Swedish developer and manufacturer of medical devices, today announced its unique CoreTherm® medical device that utilizes minimally invasive, temperature-controlled, microwave thermotherapy to treat an enlarged prostate (BPH - benign prostatic hyperplasia), which affects millions of men in the U.S.

CoreTherm effectively treats patients in 10-15 minutes, produces results equivalent to surgery, and is safer than surgery with significantly fewer serious adverse events. Because CoreTherm only requires a local anesthetic and is administered on an outpatient basis, it is especially beneficial for patients at greater risk for a surgical procedure requiring general anesthesia.

CoreTherm received FDA approval in 2003 and has successfully treated approximately 15,000 patients worldwide. It is now available to hospitals, clinics, and physicians in the U.S. and Canadian markets.

"CoreTherm is the most advanced, effective treatment for BPH available today. It provides patients with maximum positive results with minimal risk or discomfort," stated Magnus Bolmsjö, founder and CEO of ProstaLund AB. "Physicians like CoreTherm because it allows them treat a greater number of patients in a shorter amount of time, thus making the biggest improvement to their patient's conditions and quality of life."

About the Problem (Benign Prostate Hyperplasia - Enlarged Prostate)

Virtually every other man over the age of 50 will over time be affected by urination problems due to benign prostate hyperplasia, BPH. This condition causes troublesome symptoms and anxiety that adversely affects quality of life for millions of men around the world. Addressing the BPH problem often becomes a choice between surgery, a minimally invasive procedure or symptom-controlling medication.

In the past few years, a new type of minimally invasive methods to treat BPH have become the treatment of choice for more and more patients. These minimally invasive methods involve the use of microwave thermotherapy to reduce the size of the prostate. Prostalund's CoreTherm method utilizes its own innovative technologies to provide temperature feedback and control during the procedure in order to produce better results.

About CoreTherm

CoreTherm's unique features and patented design make it the most advanced minimally invasive procedure available today for the treatment of BPH. No other minimally invasive, microwave thermotherapy devices have these capabilities.

Best Results - Equivalent to Surgery: CoreTherm is the only minimally invasive microwave thermotherapy device that consistently reduces patient symptoms from severe to mild -- similar to surgery. Other minimally invasive procedures only reduce the symptoms from severe to moderate.

Safer than Surgery/Fewer Serious Adverse Events: In a 12-month follow up of a randomized multi-center study involving 146 patients, 17% of patients undergoing TURP (transurethral resection of the prostate) experienced a serious adverse event while only 2% of the CoreTherm patients experienced a serious adverse event. This study is available upon request.

Accurate Monitoring of Intraprostatic Temperature: By accurately monitoring the temperature of the prostate during the procedure, physicians can observe the condition of the patient's prostate and real-time effects of the treatment in progress. Without this monitoring, patients are frequently (up to 40%) under treated, which leads to less than optimal results or even the need to be treated again in the future.

Adjustable Microwave Power/Temperature Control: CoreTherm allows the physician to precisely adjust the temperature to treat each individual patient's condition. This control is important because it reduces the chances the prostate is either over treated or under treated.

Fastest Treatment Time: CoreTherm treats patients in 10-15 minutes, while other microwave thermotherapy devices require 30-60 minutes of treatment. Patients greatly appreciate this benefit. Surgery requires an overnight hospital stay and administration of a general anesthetic.
 

- U.S. Food and Drug Administration (FDA)
 

www.coretherm.com

 
Subscribe to Surgery Newsletter
E-mail Address:

 

About Prostalund

ProstaLund, Inc., based in Los Angeles, is a wholly owned subsidiary of Prostalund AB in Sweden. Prostalund is the developer and manufacturer of the unique and patented CoreTherm medical device for treatment of benign prostatic hyperplasia, based on a unique customized microwave treatment that takes place while monitoring the temperature of the prostate. Prostalund has approximately forty employees in Sweden, a subsidiary in Germany, and sales and distribution organizations throughout Europe, the Middle East, China and the rest of the world. The company's operations are carried out in close collaboration with leading universities and hospitals in Sweden, the U.S., and around the world.

For more information including clinical findings, sales, and distribution, contact Prostalund, Inc. at (310) 559-6015 or visit their Web site at www.coretherm.com.



Media Contact
TopSpin Communications, Inc.
Joe Waldygo
Phone: 480-632-5050
Email: [email protected]


Related Surgery News

Predicting survival in liver transplant patients
Many urinary stones can be treated without surgery
Mathematical tools for predicting facial surgery results
SALT protocol improves quality of donor lungs significantly
Costimulation blockade: Will this lead to rejection-free transplants?
Bringing space age to surgery equipment, procedures
Hepatorenal syndrome patients best benefited by a combined liver-kidney transplant
Botox Injections Help Minimize Facial Scars
Microskin relieves emotional trauma for child burn victims
'Domino' transplant program makes best use of altruistic donated kidneys


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us